PowerUp Acquisition, Visiox enter agreement for business combination

Visiox Pharmaceuticals and PowerUp Acquisition Corp. (PWUP) announced the execution of a definitive agreement for a business combination that would result in Visiox becoming a publicly traded company on the Nasdaq Capital Market. The business combination is expected to close in the first quarter of 2024, and upon closing the combined company will be named Visiox Holdings, Inc. with its common stock and warrants expected to be listed on Nasdaq under the ticker symbols VSXP and VSXPW, respectively. Visiox’s pipeline of an FDA Approved drug candidate, and other late-stage clinical drug candidates, includes treatments for patients with ocular hypertension, open angle glaucoma, and post-surgical inflammation and pain. Visiox’s mission is to develop and commercialize ophthalmic treatments in large markets with high unmet need. Visiox’s pipeline of both New Chemical Entity and 505(b)(2) products address highly prevalent disease states in need of new treatment options. Globally, glaucoma affects over 80 million people, and there are over 6 million ocular surgeries in the United States every year. Upon the closing of the Transaction, Visiox will continue to be led by current CEO, Ryan Bleeks.